Multiscale modelling of cancer response to oncolytic viral therapy

被引:52
|
作者
Alzahrani, Talal [1 ]
Eftimie, Raluca [1 ]
Trucu, Dumitru [1 ]
机构
[1] Univ Dundee, Div Math, Dundee DD1 4HN, Scotland
关键词
Multiscale modelling; Cancer modelling; Tumour-oncolytic virus interactions; MATHEMATICAL-MODEL; TUMOR-GROWTH; GLIOMA VIROTHERAPY; CELL; DYNAMICS; VIRUS; INVASION; TISSUE; HALLMARKS; DIFFUSION;
D O I
10.1016/j.mbs.2018.12.018
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Oncolytic viruses (OV) are viruses that can replicate selectively within cancer cells and destroy them. While the past few decades have seen significant progress related to the use of these viruses in clinical contexts, the success of oncolytic therapies is dampened by the complex spatial tumour-OV interactions. In this work, we present a novel multiscale moving boundary modelling for the tumour-OV interactions, which is based on coupled systems of partial differential equations both at macro-scale (tissue-scale) and at micro-scale (cell-scale) that are connected through a double feedback link. At the macro-scale, we account for the coupled dynamics of uninfected cancer cells, OV-infected cancer cells, extracellular matrix (ECM) and oncolytic viruses. At the same time, at the micro scale, we focus on essential dynamics of urokinase plasminogen activator (uPA) system which is one of the important proteolytic systems responsible for the degradation of the ECM, with notable influence in cancer invasion. While sourced by the cancer cells that arrive during their macro-dynamics within the outer proliferating rim of the tumour, the uPA micro-dynamics is crucial in determining the movement of the macro-scale tumour boundary (both in terms of direction and displacement magnitude). In this investigation, we consider three scenarios for the macro-scale tumour-OV interactions. While assuming the usual context of reaction-diffusion-taxis coupled PDEs, the three macro-dynamics scenarios gradually explore the influence of the ECM taxis over the tumour - OV interaction, in the form of haptotaxis of both uninfected and infected cells populations as well as the indirect ECM taxis for the oncolytic virus. Finally, the complex tumour-OV interactions is investigated numerically through the development a new multiscale moving boundary computational framework. While further investigation is needed to validate the findings of our modelling, for the parameter regimes that we considered, our numerical simulations indicate that the viral therapy leads to control and decrease of the overall cancer expansion and in certain cases this can result even in the elimination of the tumour.
引用
收藏
页码:76 / 95
页数:20
相关论文
共 50 条
  • [31] Multiscale moving boundary modelling of cancer interactions with a fusogenic oncolytic virus: The impact of syncytia dynamics
    Alzahrani, Talal
    Eftimie, Raluca
    Trucu, Dumitru
    MATHEMATICAL BIOSCIENCES, 2020, 323
  • [32] Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection
    Alvarez-Breckenridge, Christopher A.
    Choi, Bryan D.
    Suryadevara, Carter M.
    Chiocca, Antonio
    CURRENT OPINION IN VIROLOGY, 2015, 13 : 25 - +
  • [33] A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer
    LaRocca, Christopher J.
    Warner, Susanne G.
    BIOMEDICINES, 2018, 6 (04)
  • [34] Imaging of oncolytic viral therapies of cancer
    Thorne, S.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 : 34 - 34
  • [35] Hormonal milieu enhances the efficacy of oncolytic herpes viral therapy in prostate cancer
    Bhargava, A
    Stiles, BM
    Mullerad, M
    Gusani, NJ
    Adusumilli, P
    Kim, TH
    Fong, YM
    MOLECULAR THERAPY, 2003, 7 (05) : S368 - S368
  • [36] Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical
    Chao Tang
    Lan Li
    Tong Mo
    Jintong Na
    Zhangbo Qian
    Dianfa Fan
    Xinjun Sun
    Min Yao
    Lina Pan
    Yong Huang
    Liping Zhong
    Clinical and Translational Oncology, 2022, 24 : 1682 - 1701
  • [37] Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical
    Tang, Chao
    Li, Lan
    Mo, Tong
    Na, Jintong
    Qian, Zhangbo
    Fan, Dianfa
    Sun, Xinjun
    Yao, Min
    Pan, Lina
    Huang, Yong
    Zhong, Liping
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (09): : 1682 - 1701
  • [38] Coxsackievirus A11 as a novel oncolytic viral therapy for human colorectal cancer
    Ogata, Hisanobu
    Wang, Beibei
    Miyamoto, Shoei
    Takishima, Yuto
    Sagara, Miyako
    Murahashi, Mutsunori
    Onishi, Hideya
    Tani, Kenzaburo
    CANCER RESEARCH, 2019, 79 (13)
  • [39] Clinical development directions in oncolytic viral therapy
    R M Eager
    J Nemunaitis
    Cancer Gene Therapy, 2011, 18 : 305 - 317
  • [40] Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer
    Paiva, Leticia R.
    Silva, Hallan S.
    Ferreira, Silvio C.
    Martins, Marcelo L.
    PHYSICAL BIOLOGY, 2013, 10 (02)